CIA
MURA

Concurrent Investment Advisors’s Mural Oncology MURA Stock Holding History

Concurrent Investment Advisors’s Portfolio MURA Stock Details MURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,500
Closed -$28.4K – 1450
2025
Q1 		$28.4K Buy
+22,500
New +$82K ﹤0.01% 1210

Other funds holding MURA

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Concurrent Investment Advisors's MURA Position: Q2 2025 in Review

Concurrent Investment Advisors sold out of Mural Oncology (MURA) in Q2 2025, closing a stake of 22,500 shares — an estimated $28.4K sold.

Concurrent Investment Advisors first reported a position in MURA in Q1 2025 and held it in 1 quarter. The position peaked at $28.4K in Q1 2025. 66 funds tracked by Wall St. Rank hold MURA as of Q2 2025.

  • Concurrent Investment Advisors reported no remaining Mural Oncology position as of Q2 2025 after selling out during the quarter.
  • Concurrent Investment Advisors sold 22,500 Mural Oncology shares in Q2 2025, an estimated $28.4K.
  • Concurrent Investment Advisors first reported a position in Mural Oncology in Q1 2025 and held it in 1 quarter.
  • Concurrent Investment Advisors's Mural Oncology position peaked at $28.4K in Q1 2025.
  • 66 funds tracked by Wall St. Rank held Mural Oncology as of Q2 2025.

Based on Concurrent Investment Advisors's 13F filing for Q2 2025, filed 25 Jul 2025.